UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________________________________ FORM 10-Q _________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ ...

Financial Data and Key Metrics Changes - In 2022, the company achieved total revenue growth of 49%, reaching $149 million, with quarterly revenue growing 26% year-over-year and 29% quarter-over-quarter [5][14][15] - The company expects total net revenue for 2023 to be between $180 million and $190 million, maintaining a trajectory towards $500 million by 2028, representing a 22% compound annual growth rate [13][18][20] - The reported gross margin for Q4 was 67.7%, with an adjusted gross margin of 69.4%, reflecting a decrease in royalty obligations [29][30] Business Line Data and Key Metrics Changes - Jeuveau was noted as the fastest-growing toxin in the aesthetic market for the second consecutive year, achieving a double-digit market share [5] - The company added 700 new accounts in Q4 2022, totaling over 2,500 new customers for the year, with a reorder rate above 70% [15][16] - The Evolus Rewards Consumer Loyalty Program grew by over 75% in 2022, reaching more than half a million members [16] Market Data and Key Metrics Changes - The U.S. aesthetic neurotoxin market was estimated at approximately $2.2 billion at the end of 2022, projected to grow to around $4 billion by 2028 [19] - The company anticipates that international sales will represent 15% to 20% of total revenue by 2028, with ongoing expansion into European markets [20][21] Company Strategy and Development Direction - The company plans to expand its international presence with the launch of Nuceiva in Germany and Austria, and is preparing for a launch in Australia [6][21][108] - The strategy includes achieving positive non-GAAP operating income by the end of 2023 without needing additional capital [13][27] - The company aims to complement its product offerings through potential acquisitions to enhance market reach [39][90] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving profitability in 2023, citing a steady decrease in operating cash usage throughout 2022 [27][33] - The management noted that the underlying U.S. aesthetic market conditions remain strong, with growing consumer purchasing power fueling market expansion [107] - The company is optimistic about its growth trajectory, expecting to outpace the aesthetic neurotoxin market growth by a factor of two in 2023 [38] Other Important Information - The company reported a significant reduction in cash used for operating activities, down to $8.8 million in Q4, nearly 50% lower than the previous quarter [111] - The company resolved all litigation with Medytox, ensuring no impact on operations from ongoing legal matters [25] Q&A Session Summary Question: Insights on long-acting toxin data and market reception - Management noted significant interest from clinicians regarding the extra-strength formulation, with many expressing a desire for longer duration products [43][50] Question: Market share and growth assumptions - The company indicated that its guidance assumes existing market share and does not factor in potential benefits from new products or market growth [49][66] Question: Trends in consumer behavior in loyalty programs - Management observed no significant differences in retention rates among different demographic groups within the loyalty program [58] Question: Competitive landscape and market conditions - Management acknowledged the entry of new competitors but emphasized the healthy market conditions and ongoing demand for neurotoxins [66][103] Question: International rollout and revenue consistency - The company plans a phased international expansion, with expectations for more consistent revenue from Canada moving forward [82][85]

Product Commercialization - The company relies entirely on the successful commercialization of its only product, Jeuveau, and failure to market it effectively may hinder revenue generation [16] - Jeuveau's commercial success depends on achieving broad physician adoption and consumer demand, which may not be guaranteed [21] - The reliance on the Daewoong Agreement for exclusive distribution rights is crucial; any loss of these rights would significantly impact Jeuveau's commercialization [21] - Evolus relies on the Daewoong Agreement for exclusive rights to distribute Jeuveau in certain territories, and any loss of these rights could materially affect its commercialization efforts [21] Financial Viability - The company has incurred significant losses since inception and anticipates continued losses for the foreseeable future, complicating future viability assessments [16] - Additional financing may be required to fund future operations, and failure to secure capital could lead to operational delays or reductions [16] Regulatory Challenges - Regulatory approvals are necessary for expanding indications for Jeuveau, which could be costly and not guaranteed [21] - The company’s ability to market Jeuveau is currently limited to treating glabellar lines, necessitating further regulatory approvals for broader applications [21] - Evolus is subject to extensive government regulation, which may result in delays or additional expenses in obtaining regulatory approvals for product candidates [21] Competition - The company faces significant competition in the market, which may impede achieving substantial market penetration and expansion [21] - Jeuveau faces significant competition, and failure to effectively compete may hinder market penetration and expansion [21] Operational Risks - Compliance with settlement agreements with Medytox, Inc. is critical; non-compliance may result in litigation or loss of marketing rights for Jeuveau [16] - The terms of the Settlement Agreement with Medytox will reduce profitability and may limit discount offerings to customers [16] - The company’s operations may be adversely affected by the COVID-19 outbreak or similar events [21] - The COVID-19 outbreak has adversely affected the company’s business, financial condition, and operations, with potential future impacts [21] - The company’s operations are heavily reliant on digital technology, and any system failures or breaches could adversely impact business [21] Growth and Development - Failure to successfully in-license, acquire, develop, and market additional product candidates could impair business growth [21] - Evolus may need to increase its organization size, including sales and marketing capabilities, to further market Jeuveau, which could present management challenges [21] - There is a risk of third-party claims of intellectual property infringement that could delay commercialization efforts [21]

This presentation contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position; business strategy; the market growth for our product; our ability to meet our goals related to the market position of our product; the potential market acceptance, demand market size, adoption rate, revenue exp ...

Financial Data and Key Metrics Changes - The company reported a revenue growth of 27% year-over-year, reaching $33.9 million in Q3 2022, compared to $26.7 million in the same quarter last year [7][17] - The adjusted gross margin for Q3 was 60.2%, with a reported gross margin of 58% [21] - Non-GAAP loss from operations decreased to $13.3 million from $14.1 million in the previous quarter [24] - Cash position at the end of Q3 was $65.6 million, down from $84.5 million at the end of Q2 [25] Business Line Data and Key Metrics Changes - The "Switch Your Tox" promotional campaign led to the addition of nearly 650 new accounts, bringing the total to over 8,800 purchasing customers [10] - The Evolus Rewards program grew by almost 50,000 members in the quarter, reaching nearly 450,000 total members [10] - The average selling price of Jeuveau remained consistent with Q2 and above 2021 levels [17] Market Data and Key Metrics Changes - The company is gaining market share, now approaching 10% of the U.S. aesthetic toxin market [6][13] - Despite a seasonal dip in procedural volumes during the summer, demand for neurotoxins remains strong [12] - The aesthetic toxin market is expected to continue growing, driven by the millennial demographic [13] Company Strategy and Development Direction - The company is focused on expanding its product portfolio and geographic presence, with a recent launch in Great Britain and plans to enter other European markets [6][14] - The strategy includes targeting the millennial demographic and leveraging co-branded marketing to strengthen customer partnerships [11][30] - The company aims to achieve profitability through disciplined operating expense management and a strong cash position [6][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the resilience of the aesthetic neurotoxin market, expecting continued growth despite economic uncertainties [8][36] - The company anticipates that the majority of deferred revenue from the "Switch Your Tox" program will be recognized in Q4 2022 [19] - Management remains optimistic about 2023, forecasting growth at more than double the market average [31][36] Other Important Information - The company plans to present interim data from its Phase II extra-strength study in early 2023 [15] - The pricing environment for neurotoxin products in the U.S. remains strong, with a significant decrease in royalty obligations expected to improve margins [21] Q&A Session Summary Question: Broader market performance and expectations for 2023 - Management noted that seasonality affected procedural growth rates, but they have not observed a significant slowdown in their business [34] Question: Market opportunity for extra-strength product and European launch - There is strong interest in the extra-strength product, but regular strength is expected to remain dominant in usage [40] - The company expects to see increased contributions from international markets, particularly as they expand into Germany [41] Question: Consumer incentives during economic pressures - Management discussed the importance of co-branded media and the Evolus Rewards program to maintain consumer engagement [52] Question: Interest from accounts reconsidering their current toxin options - The company is experiencing an all-time high in new accounts purchasing, indicating a favorable market position [56]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________________________________ FORM 10-Q _________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to _______ ...

Evolus, Inc. (NASDAQ:EOLS) Q2 2022 Earnings Conference Call August 1, 2022 9:00 AM ET Company Participants David Erickson - Vice President, Investor Relations David Moatazedi - President and Chief Executive Officer Rui Avelar - Chief Medical Officer and Head of Research and Development Conference Call Participants Louise Chen - Cantor Fitzgerald Annabel Samimy - Stifel Marc Goodman - SVB Greg Fraser - Truist Securities Serge Belanger - Needham and Company Douglas Tsao - H.C. Wainwright Uy Ear - Mizuho Opera ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________________________________ FORM 10-Q _________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ ...

gg evolus™ M A Y 202 2 Investor Presentation | --- | --- | --- | |-------|-------------------|-------| | | | | | | | | | | | | | | 8 | | | | | | | | our Purpose | | | | To make the her | | | | beauty experience | | | | delightful and | | | | achievable | | Disclosures Special Note Regarding Forward-Looking Statements This presentation contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained i ...

Financial Data and Key Metrics Changes - First quarter sales grew to nearly $34 million, reflecting a year-over-year growth of 177% compared to the first quarter of 2021 [9][12] - The company expects to achieve the upper end of its full year sales guidance range of $143 million to $150 million, equating to a year-over-year growth rate approaching 50% [11][33] - Reported gross margin for the first quarter was 59%, with an adjusted gross margin of 61% [26] - Non-GAAP loss from operations improved to $10.3 million in Q1 2022 from $12.2 million in Q4 2021 [29] Business Line Data and Key Metrics Changes - The company added more than 575 new accounts in the first quarter, the highest quarterly increase in the past two years, bringing the total to over 7,500 purchasing customers [15] - The Evolus Rewards program grew to over 335,000 members, with nearly 90,000 consumers rewarded during the quarter [19][60] Market Data and Key Metrics Changes - The aesthetics market is expected to grow in the teens to up to 20%, while the company anticipates a growth rate of approximately 50% [41][55] - The pricing environment for neurotoxin products in the U.S. remains healthy, with an increase in average selling price [25][56] Company Strategy and Development Direction - The company is focused on expanding its European footprint with the launch of Nuceiva planned for the third quarter, starting in the U.K. and Germany [20][21] - Evolus aims to build a powerful brand appealing to millennials, which is expected to drive long-term growth [38] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving strong growth in 2022, supported by robust market dynamics and the successful relaunch of Jeuveau [10][41] - The company is closely monitoring macroeconomic factors like inflation and supply chain issues but believes its fixed transfer pricing will mitigate significant impacts [56] Other Important Information - The company ended the first quarter with $107 million in cash, down from $146 million at the end of 2021, but expects this balance to fund operations through cash flow breakeven [30][31] - The final installment of a $5 million settlement payment is due in Q1 2023, which will fully satisfy total milestone settlement obligations [32] Q&A Session Summary Question: Market dynamics and share gains - Management noted that the aesthetics market is experiencing significant growth, with the company benefiting from both market growth and share gains [41][44] Question: Market share evolution and macro headwinds - The company expects to continue expanding its market share, with a favorable backdrop for growth despite potential macroeconomic challenges [55][56] Question: Loyalty program progress - The loyalty program has enrolled nearly 400,000 consumers, with repeat treatments hitting an all-time high, indicating strong consumer satisfaction [60][62] Question: Business development environment - The evolving market presents opportunities for corporate development, with the company focused on durable assets to build its portfolio [67][70]